Full-Time
IQVIA
10,001+ employees
Analytics and research for life sciences
No salary listed
Senior
Company Historically Provides H1B Sponsorship
London, UK
- Degree in Information Technology, Cybersecurity, Information Systems, Computer Science, Business Administration, or related area.
- Certified in Information System Auditing or Information Security (CISA, CISSP or equivalent) with minimum 8 years of progressively responsible experience in a relevant function.
- Extensive knowledge of risks, processes, and internal controls within main IT and operational process areas.
- Exposure to Sarbanes-Oxley Act and other auditing principles including general auditing (GAAS) standards.
- Extensive knowledge and understanding of general and application controls, system/application development, business continuity and disaster recovery, data privacy, and technology areas including networks, communications, operating systems, databases, cloud computing, web technologies, and IT governance standards and industry best practices (e.g., ISO 27000, NIST, ITIL, etc.).
- International travel requirements of approximately 15%.
- Oversee management and delivery of a portfolio of IT and Operational audits, and SOX assignments as part of the annual IT Internal Audit plan.
- Manage an audit team on assigned IT and operational audits, including scoping, fieldwork, documentation of test results and workpapers, and reporting in accordance with internal and external standards.
- Support the Director of IT Internal Audit in the annual risk assessment and audit plan development process.
- Develop and leverage relationships with IQVIA management to identify and assess risks within assigned areas to determine the scope of assigned engagements.
- Prepare IT audit programs to be used in current and future audits.
- Identify internal control weaknesses, providing recommendations and follow-up on action plan implementation in partnership with key partners and business owners.
- Prepare and deliver audit reports to management, including audit observations, recommendations, and development of agreed upon management action plans.
- Conduct follow-up on remediation and management action plans with IQVIA management.
- Communicate audit status and observations, with associated recommendations, to all relevant stakeholders.
- Manage and coach junior team members assigned to audits on a project basis.
- Manage direct reports where applicable, including the performance appraisal process.
- Excellent interpersonal and communication skills and the ability to interact with senior management across countries and cultures.
- Attention to detail and organization to ensure completeness and accuracy of work performed.
- Ability to prioritize, multitask and commit to meet reporting deadlines.
- Excellent analytical, problem-solving, and decision-making skills.
- Ability to work under own initiative, and enthusiasm to drive through change.
- PC proficiency, including MS Word, Excel, Power Point, and Outlook.
- Knowledge of data analytics and usage of audit management tools including AuditBoard would be an advantage.
- High level of confidentiality when dealing with highly sensitive information and ability to work with large amounts of complex data.
- Proven track record of working with senior management across IT, Legal, and Privacy business functions.
- Ability to quickly learn new technologies as they become prevalent and widely implemented.
- Comfortable with ambiguity and can make quality decisions in a dynamic, fast-paced environment.
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main product, IQVIA Connected Intelligence™, utilizes large datasets and technology to offer quick insights that help clients speed up the development and marketing of new medical treatments. This service is designed to improve healthcare outcomes by connecting various aspects of healthcare. What sets IQVIA apart from its competitors is its strong focus on patient privacy, employing advanced technologies to protect individual data. The company's goal is to enhance understanding of diseases and human behaviors, ultimately contributing to the development of cures.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- IQVIA's Med-R1 8B LLM enhances clinical data interpretation for healthcare professionals.
- Recognition in IDC MarketScape boosts IQVIA's credibility in decentralized clinical trials.
- Site Lab Navigator streamlines lab workflows, transforming clinical trial processes.
What critics are saying
- CAR T-cell therapy access disparities may affect IQVIA's reputation.
- Competition in AI models could impact Med-R1 8B's market share.
- Existing lab automation solutions challenge Site Lab Navigator's adoption.
What makes IQVIA unique
- IQVIA's Connected Intelligence™ offers rapid insights for healthcare innovation.
- The company excels in protecting patient privacy with advanced technologies.
- IQVIA's global presence spans over 100 countries with 86,000 employees.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%
LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ - Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments.
IQVIA has launched Med-R1 8B, a medical reasoning large language model (LLM) designed to assist healthcare professionals in interpreting complex clinical data and scientific literature.
COLLEGE PARK, Md., March 26, 2025 /PRNewswire/ -- Registration is open for "Business of Life Sciences and Healthcare for Leaders" (B-LSHC) — an immersive five-day program focused on leadership development and honing critical-thinking and problem-solving skills in medical product development presented by Smith Executive Education at the University of Maryland's Robert H. Smith School of Business.The in-person program takes place June 23-27, 2025, at Van Munching Hall on UMD's College Park campus and is designed for mid-to-advanced career professionals in the LSHC ecosystem including pharmaceutical, biotech and medical device industries; health policy; patient advocacy; regulators; investors; and leaders across medical and regulatory fields.Program sessions will begin at 8:30 a.m. each day "and end with a luminary keynote speaker who will inspire and challenge participants to think outside the box toward the goals of creating innovative solutions for some of our most challenging problems in the LSHC ecosystem," says Wendy Sanhai, PhD, professor of the practice in management and organization for the Smith School and one of the workshop's organizers.Participants will learn from world-renowned faculty, regulatory experts and industry leaders on how to make informed decisions at crucial stages of medical product (drugs, biologics and medical devices) development – from R&D and regulatory submission to commercial launch and reimbursement. And, through expert-led sessions, dynamic capstone project discussions and case-study analysis, participants will sharpen their problem-solving and critical-thinking skills as they expand their professional network.Instructors, in addition to Sanhai, will include UMD and Smith faculty experts Balaji Padmanabhan, director of Smith's Center for Artificial Intelligence in Business; management and organization professors Jennifer Carson Marr, Oliver Schlake and Subra Tangirala; marketing professor Judy Frels; School of Public Health Dean Boris Lushniak; and School of Pharmacy Professor Joga Gobburu.The UMD experts will be joined by leading industry experts including former CEO of Scorpion Therapeutics Axel Hoos, IntoValue CEO Marion Couch, Deloitte Principals Juergen Klenk, Candy Lurken and Mathias Cousin; Euclidean Life Science Advisors President Kenneth Moch; Licensing IP negotiator Steve Ferguson; leaders from IQVIA and former FDA leaders.Participants will:Sharpen problem-solving, leadership and critical-thinking skillsCultivate holistic thinking and multidisciplinary approaches for real-world problems in the LSHC ecosystemBuild upon lessons learned and best practices from regulatory experts, industry luminaries and academic leadersExpand their professional networkIdentify major milestones, potential challenges, risks and mitigation strategies across medical product development pathways in R&D, regulatory submission, product launch and commercializationExecute critical steps in license negotiations and technology transfer processesParticipants should have at least a bachelor's degree and five years of working experience in any LSHC field.Scholarships are available, including for nonprofits, government professionals and veterans. Discounts are available for organizations with multiple participants. Information sessions via Zoom are set for 1-2 p.m
IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the "Leaders" category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment.